Micropulse Trans-scleral Cyclophotocoagulation for the Treatment of Glaucoma - The Yale Study

MicroPulse® P3 Glaucoma Device (MP3) Innovative Cyclophotocoagulation with MicroPulse Technology Powered by the NEW CYCLO G6™ Glaucoma Laser System  | Source: iridex.com

One-Year Results of Micropulse Trans-scleral Cyclophotocoagulation for the Treatment of Glaucoma – The Yale Study

Micropulse Trans-scleral Cyclophotocoagulation using the IRIDEX P3 handpiece (aka TS-CPC or MP3) is a relatively new take on a glaucoma laser treatment that has been around for decades. As a recent innovation, most studies reported to date have only short-term (3 or 6 month) data. For a glaucoma treatment to be of true benefit to most patients, however, it needs to work over a period of years, not months.

Doctors Alexander Nguyen and Robert Noecker recently addressed this issue in a paper presented at the American Glaucoma Society (AGS) 2017 Annual Meeting in Coronado, CA. They reviewed the charts of 95 patients with glaucoma who had undergone Micropulse Trans-scleral Cyclophotocoagulation and had been followed for at least a year after surgery.

The average IOP prior to this glaucoma treatment was 25.1mmHg. One year after MP3 the average IOP dropped to 17.4mmHg (30.7% reduction). Additionally, the need for glaucoma medications decreased by 50%. Of particular interest is that, on average, MP3 reduced intraocular pressure (IOP) as well as need for IOP-lowering medications at every post-operative visit. In other words, the benefit was both immediate and long-term.

One year after MP3 the average IOP dropped to 17.4mmHg (30.7% reduction)

Retreatment was necessary in 23% of those who had MP3. The most common side effect was inflammation which was present early after surgery. No one in this study experienced long-term inflammation or hypotony (IOP that is too low). A sustained increase in pupil size was noted in 3 patients (0.3%).

In summary, Micropulse Trans-scleral Cyclophotocoagulation appears to be a relatively safe and effective treatment of glaucoma with both short and long-term benefit.

Need Help with Your Glaucoma?

Learn more about this blinding disease. Know your treatment options. Talk to a board-certified Ophthalmologist who is an expert in the treatment of glaucoma and cataract.

David Richardson, MD

David Richardson, MD

Medical Director, San Marino Eye

David Richardson, M.D. is recognized as one of the top cataract and glaucoma surgeons in the US and is among an elite group of glaucoma surgeons in the country performing the highly specialized canaloplasty procedure. Morever, Dr. Richardson is one of only a few surgeons in the greater Los Angeles area that performs MicroPulse P3™ "Cyclophotocoagulation" (MP3) glaucoma laser surgery. Dr. Richardson graduated Magna Cum Laude from the University of Southern California and earned his Medical Degree from Harvard Medical School. He completed his ophthalmology residency at the LAC+USC Medical Center/ Doheny Eye Institute. Dr. Richardson is also an Ambassador of Glaucoma Research Foundation.

Pin It on Pinterest

Share This Page

Share information about glaucoma with your friends and family!